Business Context and Reporting Period
This Form 8-K is filed by First Light Acquisition Group, Inc. (not Calidi Biotherapeutics, Inc.) for the reporting period of December 21, 2022. The filing addresses a material change in corporate governance and executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Bill Weber resigned effective immediately on December 21, 2022, from his positions as co-Chief Executive Officer, Director, and Chairman of the Board.
- Reason for Departure: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Leadership Transition: Effective December 22, 2022, Thomas A. Vecchiolla assumed the roles of sole Chief Executive Officer and Chairman of the Board.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the leadership transition. No unusual items were reported.
Investor Verification Checklist
- Verify the effective date of Thomas A. Vecchiolla's appointment as sole CEO and Chairman.
- Confirm the absence of any undisclosed disagreements related to Bill Weber's departure.
- Review subsequent filings for any impact of this leadership change on the Company's business combination strategy or operational plans.